Ordering name: SDT fatty/Jcl
Availability: Live colony
In 2004, Dr. Masuyama and Dr. Shinohara (Research Laboratories of Torii Pharmaceutical Co., Ltd., Japan) established the congenic type 2 diabetes model Spontaneously Diabetic Torii fatty (SDT fatty) rat by introducing the fa allele of the Zucker Fatty rat into the genome of the original SDT rat 1). SDT fatty rats were introduced to Central Pharmaceutical Research Institute, Japan Tobacco Inc. (Japan) and were characterized in detail by Dr. Ohta and Dr. Sasase. CLEA Japan has received right of production and sales from Japan Tobacco Inc., and has distributed the animals as SDT fatty rats from 2012.
◇ Reference(*This PDF data includes Japanese.)
Introduction of SDT fatty rat
Various Diabetic Complications can be observed.(Nephrology, Retinopathy, and Cardiovascular)
Secondary Sarcopenia： SDT fatty rat, spontaneous type 2 diabetic animal model
SDT fatty rat, spontaneously type 2 diabetes animal model, shows the symptoms of secondary sarcopenia related with diabetes and obesity.
Cholesterol-Loaded NASH: SDT fatty rats, type 2 diabetes and obesity model
By cholesterol loading, Obesity type 2 diabetes model SDT fatty rats shows human-like NASH pathology characteristics after 24 weeks of age.
High-sucrose/high-fat diet promotes nephropathy: Introduction of obese type 2 diabetes model SDT fatty rats
High sucrose/high fat diet (Quick Fat; QF) load Obese type 2 diabetes model SDT fatty rats show signs of Diabetic Kidney Disease (DKD) development at 28 weeks of age, showing characteristics as a useful DKD model.
Diabetic peripheral neuropathy in SDT fatty rat, a new animal model of obese type 2 diabetes
Peripheral neuropathy due to diabetes and drug effects of SGLT inhibitor (Phlorizin) can be observed. Introduction of CLEA Japan's type 2 diabetes model, SDT fatty rats